BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Thermage, Inc. Schedules Shareholder Meeting for Vote on the Issuance of Common Stock in Connection With the Reliant Acquisition


11/25/2008 9:52:27 AM

HAYWARD, Calif., Nov. 24 /PRNewswire-FirstCall/ -- Thermage, Inc. today announced that its S-4 Registration Statement, filed with the Securities and Exchange Commission regarding its proposed acquisition of Reliant, Inc., has been declared effective. The proxy will be mailed beginning on or about November 25, 2008 to shareholders of record as of October 31, 2008. The Company has set a date of Tuesday, December 23 for a meeting of its shareholders to vote on the issuance of common stock in connection with the proposed acquisition. The meeting will be held at Thermage's corporate offices at 25881 Industrial Boulevard, Hayward, California 94545 at 9:00 a.m. PST.

"Scheduling the shareholder meeting was a significant step, and we are very happy to be moving forward to complete this transaction, which we believe offers many benefits to our customers and shareholders," said Stephen J. Fanning, Chairman of the Board, President and CEO of Thermage. "The proposed transaction combines two well-recognized and respected brands in the aesthetics device industry. Both Thermage and Reliant are known for their innovation and our combination will offer opportunities for an expanded market presence through the cross-selling of our products. Both of our business models generate substantial recurring revenue. Finally, we have identified significant cost savings that should enhance the efficiency of our operations. We are very excited about this transaction and, pending shareholder approval, are on-track to close by year-end."

About Thermage

Thermage's innovative technology provides a unique non-invasive procedure designed to tighten and contour skin, significantly expanding the non-invasive aesthetic applications physicians can offer to the rapidly growing "anti-aging" market. For more information about Thermage, call 1-510-259-7117 or log on to http://www.thermage.com.

Additional Information and Where You Can Find It

This communication may be deemed to be solicitation material in respect of the proposed transaction between Thermage and Reliant. In connection with the transaction, Thermage has filed a registration statement on Form S-4 with the SEC containing a proxy statement/prospectus/ information statement. The proxy statement/prospectus/information statement will be mailed to the stockholders of Thermage and Reliant. Investors and security holders of Thermage and Reliant are urged to read the proxy statement/prospectus/information statement when it becomes available because it will contain important information about Thermage, Reliant and the proposed transaction. The proxy statement/prospectus/information statement (when it becomes available), and any other documents filed by Thermage with the SEC, may be obtained free of charge at the SEC's web site at http://www.sec.gov. In addition, investors and security holders may obtain free copies of the documents filed with the SEC by Thermage by contacting Thermage Investor Relations by e-mail at IR@thermage.com or by telephone at (510) 259-7117. Investors and security holders are urged to read the proxy statement/prospectus/information statement and the other relevant materials when they become available before making any voting or investment decision with respect to the proposed transaction.

CONTACT: Company, Jack Glenn, Chief Financial Officer of Thermage, Inc.,
+1-510-786-6890; or Investors, Doug Sherk, or Jenifer Kirtland,
+1-415-896-6820, or Media, Steve DiMattia, +1-646-201-5445, all of EVC
Group, Inc., for Thermage, Inc.

Web site: http://www.thermage.com/



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES